Synovics Pharma Names New President/COO

PharmaManufacturing.com
04/30/2007

Synovics Pharmaceuticals, Inc., Phoenix, Ariz., on Apr. 24 announced that David Coffin-Beach, Ph.D., has been appointed president and chief operating officer. In this role he will be responsible for, and have reporting to him management of, the Company's operating subsidiaries, Kirk Pharmaceuticals, Inc., ANDAPharm, Inc. and Synovics Laboratories, Inc.

Most recently, Coffin-Beach was a consultant with VCG & A, Inc. (VCG), where he consulted with key management of Kirk Pharmaceuticals and ANDAPharm. Previously, he served as president of Gilberts ATP, a private consulting firm and served for 11 years as president and director of TorPharm, Inc., a division of Apotex, Inc. During that period, TorPharm grew from two to more than 1,000 employees, and his division's revenue increased from zero to more than $400 million. Prior to TorPharm, Coffin-Beach worked for Schering-Plough, Goldline Laboratories, and DuPont Pharmaceuticals (Endo Laboratories) in various managerial, R&D and product development roles. He received his Ph.D. in Industrial Pharmacy from the University of Maryland in 1982.

"The appointment of a leader with the experience and record of achievement of Dr. Coffin-Beach is a significant milestone for Synovics," said Ronald H. Lane, Ph.D., Synovics' chairman and chief executive officer. "David's timely addition brings not only strong technical skills and experience in drug formulation, product development and FDA drug filings, but also experience as the managerial lead of a very successful 'green field' start-up at TorPharm. Our board of directors believes David will be a great fit in the organization, and that his knowledge, skills and influence will add to the momentum we are seeing throughout the Company. In combination with this appointment, I have resigned as president of Synovics."

Coffin-Beach commented, "I am pleased to join the Synovics team and believe that I can assist to further build on the current Company foundation and create tangible growth and success in the near term. The introduction of the omeprazole OTC product license announced last month is the first in a series of drug candidates that VCG is working to bring to the Company over the next several months. At Synovics, we are executing on a solid business plan designed to leverage the Company's strategic industry advantages in combination with resources from VCG and other potential partners, and we are well-positioned to take advantage of both the OTC and prescription businesses where we see significant growth opportunities."

Synovics is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of prescription Oral Control Release (ORC) generic and Immediate Release (IR) drugs, improved formulations of previously approved drugs and Over the Counter (OTC) drugs. For more information, visit www.synovics.com.